S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

VistaGen Therapeutics Stock Forecast, Price & News

-0.13 (-7.22%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.24 million shs
Average Volume
2.33 million shs
Market Capitalization
$333.50 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VistaGen Therapeutics logo

About VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder (SAD); PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD); and AV-101 which the company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.09 million
Book Value
$0.40 per share


Net Income
$-17.93 million
Net Margins
Pretax Margin




Free Float
Market Cap
$333.50 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.19 out of 5 stars

Medical Sector

403rd out of 1,388 stocks

Pharmaceutical Preparations Industry

183rd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

Is VistaGen Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VistaGen Therapeutics stock.
View analyst ratings for VistaGen Therapeutics
or view top-rated stocks.

How has VistaGen Therapeutics' stock been impacted by Coronavirus (COVID-19)?

VistaGen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VTGN shares have increased by 234.0% and is now trading at $1.67.
View which stocks have been most impacted by COVID-19

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for VistaGen Therapeutics

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.02. VistaGen Therapeutics had a negative net margin of 2,183.17% and a negative trailing twelve-month return on equity of 36.41%. During the same period last year, the business posted ($0.05) EPS.
View VistaGen Therapeutics' earnings history

What price target have analysts set for VTGN?

3 brokerages have issued 1-year target prices for VistaGen Therapeutics' stock. Their forecasts range from $5.00 to $9.00. On average, they expect VistaGen Therapeutics' share price to reach $6.67 in the next year. This suggests a possible upside of 299.2% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are VistaGen Therapeutics' key executives?

VistaGen Therapeutics' management team includes the following people:
  • Shawn K. Singh, Chief Executive Officer & Director
  • H. Ralph Snodgrass, President & Chief Scientific Officer (LinkedIn Profile)
  • Jerrold D. Dotson, Chief Financial Officer, Secretary & VP
  • Mark A. Smith, Chief Medical Officer
  • Ellis Wilson, Vice President-Global Clinical Operations

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.09%), Franklin Resources Inc. (5.25%), Commodore Capital LP (2.66%), Sphera Funds Management LTD. (1.98%), Geode Capital Management LLC (1.60%) and Goldman Sachs Group Inc. (0.84%). Company insiders that own VistaGen Therapeutics stock include H Ralph Snodgrass and Jerrold Duane Dotson.
View institutional ownership trends for VistaGen Therapeutics

Which major investors are selling VistaGen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Schonfeld Strategic Advisors LLC, California State Teachers Retirement System, Morgan Stanley, Cubist Systematic Strategies LLC, Two Sigma Investments LP, Deutsche Bank AG, and New York State Common Retirement Fund.
View insider buying and selling activity for VistaGen Therapeutics
or view top insider-selling stocks.

Which major investors are buying VistaGen Therapeutics stock?

VTGN stock was acquired by a variety of institutional investors in the last quarter, including Commodore Capital LP, Goldman Sachs Group Inc., EAM Global Investors LLC, Two Sigma Advisers LP, EAM Investors LLC, Victory Capital Management Inc., Millennium Management LLC, and Rafferty Asset Management LLC.
View insider buying and selling activity for VistaGen Therapeutics
or or view top insider-buying stocks.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $1.67.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics has a market capitalization of $333.50 million and generates $1.09 million in revenue each year. The company earns $-17.93 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does VistaGen Therapeutics have?

VistaGen Therapeutics employs 21 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

Where are VistaGen Therapeutics' headquarters?

VistaGen Therapeutics is headquartered at 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 577-3600, via email at [email protected], or via fax at 888-482-2602.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.